Association between GLP-1 receptor gene polymorphisms with reward learning, anhedonia and depression diagnosis

Author for correspondence:
Hale Yapici-Eser, Email: hyapici@ku.edu.tr

Hale Yapici-Eser[1,2] ⓘ, Vivek Appadurai[3,4], Candan Yasemin Eren[2], Dilek Yazici[1], Chia-Yen Chen[5,6], Dost Öngür[6,7], Diego A. Pizzagalli[6,8], Thomas Werge[3,4,9] and Mei-Hua Hall[6,7,10]

[1]School of Medicine, Koç University, İstanbul, Turkey; [2]Research Center for Translational Medicine, Koç University, İstanbul, Turkey; [3]The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH, Aarhus, Denmark; [4]Institute of Biological Psychiatry, Mental Health Center St. Hans, Mental Health Services Copenhagen, Roskilde, Denmark; [5]Psychiatric and Neurodevelopmental Genetics Unit and Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA, USA; [6]Department of Psychiatry, Harvard Medical School, Boston, MA, USA; [7]Schizophrenia and Bipolar Disorder Research Program, McLean Hospital, Belmont, MA, USA; [8]Center for Depression, Anxiety and Stress Research, McLean Hospital, Belmont, MA, USA; [9]Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark and [10]Psychosis Neurobiology Laboratory, McLean Hospital, Harvard Medical School, Belmont, MA, USA

Abstract

Background: Glucagon-like peptide-1 receptors (GLP-1Rs) are widely expressed in the brain. Evidence suggests that they may play a role in reward responses and neuroprotection. However, the association of GLP-1R with anhedonia and depression diagnosis has not been studied. Here, we examined the association of GLP-1R polymorphisms with objective and subjective measures of anhedonia, as well as depression diagnosis. *Methods:* Objective [response bias assessed by the probabilistic reward task (PRT)] and subjective [Snaith-Hamilton Pleasure Scale (SHAPS)] measures of anhedonia, clinical variables and DNA samples were collected from 100 controls and 164 patients at McLean Hospital. An independent sample genotyped as part of the Psychiatric Genomics Consortium (PGC) was used to study the effect of putative GLP-1R polymorphisms linked to response bias in PRT on depression diagnosis. *Results:* The C allele in rs1042044 was significantly associated with increased PRT response bias, when controlling for age, sex, case-control status and PRT discriminability. AA genotype of rs1042044 showed higher anhedonia phenotype based on SHAPS scores. However, analysis of PGC major depressive disorder data showed no association between rs1042044 and depression diagnosis. *Conclusion:* Findings suggest a possible association of rs1042044 with anhedonia but no association with depression diagnosis.

Significant outcomes

- rs1042044 is significantly associated with reward learning and anhedonia.
- No association between putative GLP-1R polymorphisms and depression diagnosis has been found.
- Further studies are needed to evaluate the role of GLP-1R polymorphisms in the course and severity of reward-related disorders.

Limitations

- This study has a relatively small sample size for the reward learning analysis.
- Depression is a multifactorial diagnosis and we could not consider other environmental variables in the analysis for depression.

Introduction

Mood disorders are one of the most costly and debilitating psychiatric conditions worldwide, and are associated with impairments, as disrupted reward processing. Patients with mood disorders show deficits in reward learning and they present with anhedonia (Sharma *et al.*, 2015; Lewandowski *et al.*, 2016). Reduced reward sensitivity is also considered a core feature of depression (Nusslock & Alloy, 2017). Disrupted reward learning correlates with mood fluctuations (Peterson *et al.*, 2011) and predicts persistence of depressive symptoms (Vrieze *et al.*, 2013). However, altered reward processing is not unique to mood disorders as major depressive

disorder (MDD), since it has emerged also in schizophrenia (SZ) spectrum disorders, substance use disorders and other behavioural addictions (Luijten *et al.*, 2017).

Dopaminergic signalling and frontostriatal circuits have been hypothesised to play an essential role in the reward system. However, reward processing includes pleasure, motivation, satiety, salience and even trust that are modulated by various neuromodulators (Dichter *et al.*, 2012). Also, reward prediction, evaluation and learning contribute to reward processing and they are suggested to have different neuroanatomical correlates that may be specifically targeted by specific neuromodulators (Delgado *et al.*, 2005). Therefore, it is essential to understand the other neuromodulators that take part in reward processing which may ultimately yield better treatment targets and neuropathological markers (Gold *et al.*, 2018). As one of these neuromodulators, glucagon-like peptide-1 (GLP-1) is likely to play a role in modulating reward circuitry. Current evidence links GLP-1 with food-related reward (Skibicka, 2013), social reward (Clark-Elford *et al.*, 2014), stress (Rinaman & Rothe, 2002) and despair-like behaviours (Sharma *et al.*, 2015; Anderberg *et al.*, 2016).

GLP-1 is an incretin hormone secreted by intestinal cells in response to food consumption. Its main role has been explored for peripheral blood glucose level regulation and control of type 2 diabetes mellitus (Aroda, 2018). On the other hand, GLP-1 can also be produced centrally by neurons of the nucleus tractus solitarius and microglia (Kappe *et al.*, 2012) by cleavage of preproglucagon and act through GLP-1 receptors (GLP-1Rs) in the brain (GLP-1R).

Critically, GLP-1Rs are widely expressed in reward-related regions, such as the hypothalamus, amygdala, nucleus accumbens, paraventricular nucleus, ventral tegmental area, locus coeruleus and brainstem (Heppner *et al.*, 2015), and have been found to modulate food-related activation in the insula and putamen (Farr *et al.*, 2016). All GLP-1Rs are stimulatory G protein coupled and when activated, they cause increases in cAMP and intracellular calcium, activate protein kinase A and induce gene transcription (Drucker, 2006). These receptors are expressed in both dendrites and synapses of neurons, in addition to glial cells (Chowen *et al.*, 1999). Evidence from animal and molecular studies suggests that they may have a role in reward processing and neuroprotection. Overexpression/upregulation of GLP-1R or modulating GLP-1R functions by using pharmaceutical agents that can pass the blood–brain barrier promotes learning of spatial tasks, memory formation, synaptic plasticity, neurite outgrowth and neurogenesis (Erbil *et al.*, 2019).

Animal studies also support a role of GLP-1 with reward responses and depression. Activation of GLP-1R reduces cocaine-mediated behaviours and modulates substance use through regulating dopamine release (Hernandez *et al.*, 2019) and corticosterone levels through corticotropin releasing hormone (CRH) function in the hypothalamus–pituitary–adrenal (HPA) axis (Zheng *et al.*, 2019). More specifically, GLP-1R knock-down rats showed prolonged corticosterone levels after stress induction (Zheng *et al.*, 2019) and administration of exendin-4, which is a GLP-1R agonist, increased plasma levels of ACTH (Malendowicz *et al.*, 2003) and corticosterone in plasma of rats (Malendowicz *et al.*, 2003; Krass *et al.*, 2012) and mice (Krass *et al.*, 2015), suggesting a role of GLP-1 on regulating HPA axis. GLP-1 neurons synapse on CRH neurons of paraventricular nucleus (Sarkar *et al.*, 2003) and restraint stress in mice changes GLP-1 function (Williams *et al.*, 2018). Prenatal stress reduces GLP-1R levels in

hippocampus and hypothalamus (Detka *et al.*, 2019). GLP-1 levels alter glutamatergic transmission and excitotoxicity (Koshal *et al.*, 2018), and increased GLP-1R levels improve neurogenesis and decrease cell loss in hippocampal area (Erbil *et al.*, 2019). Decreased hippocampal neurogenesis, neuronal atrophy and synaptic loss in the hippocampus represent key neurobiological findings of stress-related disorders and anhedonia (Duman & Aghajanian, 2012). Chronic central administration (Anderberg *et al.*, 2016) or injection (Sharma *et al.*, 2015) of GLP-1 agonists decreases despair-like behaviour and has an antidepressant-like effect measured by mobility in forced swim test in rats, although two studies found no change in anxiety (assessed using light-dark box) and mobility (assessed using forced swim test) after acute (Krass *et al.*, 2012) or 2-week (Krass *et al.*, 2015) treatments of GLP-1 agonist administration in mice. GLP-1 changes serotonin turnover in the amygdala (Anderberg *et al.*, 2016) and affects basal serotonin levels (Brunetti *et al.*, 2008). GLP-1 also acts on oxytocin and NPY neurons, which regulate social rewards and resilience to stress (Clark-Elford *et al.*, 2014).

These preclinical findings highlight the effects of GLP-1 on reward circuitry, depressive behaviours and stress, suggesting that GLP-1 is a promising candidate for modulating reward learning in humans. However, as evidence from animal studies on the effect of GLP-1 on neuroprotection and reward responses is accumulating, there is limited human research testing its relationship with depressive episode and reward learning. In humans, GLP-1R polymorphisms may modulate basal GLP-1 levels (de Luis *et al.*, 2015), and importantly, a recent post-mortem study found that, compared to healthy controls, patients with MDD diagnosis had decreased GLP-1R expression in the dorsolateral prefrontal cortex and hippocampus, even when adjusting for age, sex, treatments, substance use and body mass index (Mansur *et al.*, 2019).

Aims of the study

Building on this knowledge, in the current study, we first aimed to assess the association of GLP-1R polymorphisms with reward learning in a case-control sample, using a well-established laboratory-based task, the probabilistic reward task (PRT). Reward learning includes processes that shape the experience-dependent learning that guides future behaviours, and is used to assess how participants modulate their behaviour as a function of rewards (Pizzagalli *et al.*, 2005). Total response bias measured by PRT is used to capture reward learning. We predicted that GLP-1R polymorphisms modulated response bias in PRT, regardless of a psychiatric diagnosis. Secondly, we tested the effect of GLP-1R polymorphisms on a subjective measure of anhedonia (Rizvi *et al.*, 2016) using the Snaith-Hamilton Pleasure Scale (SHAPS) (Snaith *et al.*, 1995; Rizvi *et al.*, 2016). SHAPS probes the capacity to experience pleasure over the past few days. In the association analyses, we adjusted for clinical measures that could be the potential moderators of response bias, such as the General Distress related to Anxiety (GDA) and Anxious Arousal (AA) subscales of the Mood and Anxiety Symptom Questionnaire (MASQ), the Montgomery Asberg Depression Rating Scale (MADRS), Positive and Negative Symptom Scale (PANSS) and the Young Mania Rating Scale (YMRS). Lastly, we tested the effect of putative GLP-1R polymorphisms linked to response bias with lifetime depression diagnosis by examining the association of GLP-1R polymorphisms with depression diagnosis using summary statistics from the GWAS of MDD from the Psychiatric Genomics Consortium (PGC) (Wray *et al.*, 2018).

Materials and methods

Association of GLP-1 polymorphisms with reward learning and anhedonia

In order to assess the effect of GLP-1R polymorphisms on reward learning, we first analysed each GLP-R polymorphism's impact on reward learning using data from a case-control cohort from McLean Hospital (Hall *et al.*, 2015; Lewandowski *et al.*, 2016). For a stringent test, analyses were corrected for possible moderator variables that could affect reward learning. As reward learning dysfunction is found across diagnostic boundaries, including MDD, bipolar disorder (BPD) and SZ (Pizzagalli *et al.*, 2008; Whitton *et al.*, 2015) diagnoses, our study cohort included patients with mood disorders, psychotic disorders and healthy controls.

Participants

Data from 264 participants [100 healthy controls and 164 patients; 126 females (47.7%), 138 males (52.3 %)] were available for analyses. All subjects were assessed using the Structured Clinical Interview for DSM-IV (Allen, 1998). Patients were recruited through the SZ and BPD program at McLean Hospital. Of the 164 patients who had a history of lifetime psychotic episode, 70 were diagnosed with a SZ spectrum disorder, 92 with bipolar disorder and 2 with a MDD. Patients were included if they had no substance abuse (excluding nicotine) in the preceding 6 months or dependence in the preceding 12 months and no history of seizures or ECT treatment in the preceding 12 months. The control sample was recruited through local advertisements. Additional inclusion criteria for controls were no current or past history of psychotic disorder, bipolar disorder or SZ, no affective disorder in the preceding 12 months, no substance abuse in the preceding 12 months or previous chronic dependence, and no first-degree relative with a history of psychosis or bipolar disorder. All subjects self-reported European ancestry, which was confirmed based on principal component analyses of genotype data. All participants were between 18 and 69 years old (range: 18–69, mean ± SD: 38.8 ± 13.8) with no known neurological disorder, no prior head injury with loss of consciousness, normal hearing confirmed by audiometry and normal intellectual ability based on the North American Adult Reading Test or years of education (high school level or higher). As dysfunction of reward learning is found trans-diagnostically (Pizzagalli *et al.*, 2008; Whitton *et al.*, 2015), analyses used case-control status as a moderator variable, instead of splitting into diagnostic groups. This study was approved by McLean Hospital Institutional Review Board. All subjects provided a written informed consent and procedures were in accordance with the Declaration of Helsinki.

Evaluation of reward learning

The PRT was used to derive an objective measure of reward learning and has been described in detail (Pizzagalli *et al.*, 2005; Pizzagalli *et al.*, 2008). The task includes 3 blocks with 100 trials each. In each trial, participants are shown a face with a long (13 mm) or short (11.5 mm) mouth and instructed to decide whether the mouth was long or short, as quickly and accurately as possible. They are further instructed that correct responses would be followed by a monetary reward ('Correct. You won 20 cents') but that not every correct answer would be followed by a monetary reward. Unbeknownst to participants, one stimulus is rewarded three times more frequently than the other, which induces a response bias, that is, a preference for the stimulus paired with more reward in the past. Using signal-detection theory, performance can be decomposed into response bias and discriminability. Response bias measures subject's preference for the response paired with the more frequent reward and discriminability measures how well the participant can differentiate between two very close visual stimuli. Here, we used total response bias scores as the major outcome variable to detect reward learning.

Self-Report measurement of anhedonia and other psychiatric symptom scales

All participants were also evaluated with clinical scales to control for other variables that could moderate reward responses and anhedonia, and to document the clinical status of the patients. The SHAPS was used to assess subjective anhedonia (Snaith *et al.*, 1995). While scoring, the answer of each item of SHAPS scale was converted to binary categories (0 and 1), so that the total score ranged between 0 and 14 and higher scores indicated higher anhedonia. Participants with scores higher or equal to 3 in SHAPS score were recategorised as the anhedonic group (Snaith *et al.*, 1995; Franken *et al.*, 2007).

The GDA and AA subscales of the MASQ were used to assess anxiety symptoms. The MADRS was used to assess depression severity. PANSS scales were used to evaluate symptoms related to psychosis, and the YMRS was used to evaluate (hypo)manic symptoms.

Selection of GLP-1R polymorphisms and genotyping procedure

The sample reported in this study was part of a larger genome-wide association study (GWAS) previously published (Hall *et al.*, 2015). GLP-1 gene lies in the 6p21.2. Results from previous genetic studies on the role of GLP-1R polymorphisms revealed associations with peripheral effects such as weight loss after obesity surgery (de Luis *et al.*, 2014a), insulin resistance and obesity complications (Sathananthan *et al.*, 2010; de Luis *et al.*, 2014b), as well as central effects as antipsychotic response (Ramsey & Brennan, 2014) and stress and cortisol responses (Sheikh *et al.*, 2010). We reviewed the current literature for GLP-1R single nucleotide polymorphisms (SNPs) and found nine SNPs in the GLP-1R gene, which are not in linkage disequilibrium, for an association analysis and seven could be genotyped in our sample: rs10305420, rs10305421, rs1042044, rs6923761, rs587654, rs761386 and rs10305492. Of the seven SNPs examined here, rs10305420 and rs1042044 were genotyped and remaining were imputed by author CHC, since the polymorphism was not included in the CHIP. Genotype imputation was performed using a two-step pre-phasing and imputation procedure implemented in SHAPEIT (O'Connell *et al.*, 2016) and IMPUTE2 (Howie *et al.*, 2011) on a total of 1293 psychosis patients and 381 healthy controls collected at McLean Hospital that included the samples described above (Hall *et al.*, 2015). We divided the genome into 3 Mb partitions and performed pre-imputation quality control and imputation with the default parameters of the software. The pre-imputation quality control filters include discordant sex information, missing genotype rate per individual, heterozygosity rate, call rate per SNP and deviation from Hardy–Weinberg equilibrium. We used phased haplotypes from the full 1000 Genomes Project dataset (Altshuler *et al.*, 2015) as the imputation reference panel.

Statistics

Genotypes of GLP-1R polymorphisms were compared for the mean response bias scores in the PRT and anhedonia scores measured by SHAPS scale, using Mann Whitney *U* test for dominant models. The anhedonic group defined based on SHAPS score was

then compared to non-anhedonic group for the distribution of the significant dominant genotype, using chi-square test. Next, to control for possible moderator variables that could have an effect on response bias, a multivariate linear regression model was used. In the first model, age, sex, discriminability in the PRT task and case-control status were included, in addition to the SNP genotype (in dominant model) found to be significantly associated with response bias. Recent literature points that episodic memory and other cognitive features, in addition to negative symptoms may affect reward learning (Wimmer *et al.*, 2014; Lewandowski *et al.*, 2016). In the second model, instead of case-control status, clinical variables that may affect response bias such as GDA and AA subscales of MASQ, YMRS, PANSS total and MADRS were also included in the model, to control possible associations for moderator variables as cognitive and negative symptoms (Wimmer *et al.*, 2014; Lewandowski *et al.*, 2016).

P values were not corrected for multiple comparison after the first-level analysis (Mann Whitney *U* test); however, the significance of associated SNPs was further tested for their association with response bias in the second-level analysis of regression models. In addition, the association signals found were tested using an independent cohort of patients with depression diagnosis and controls from PGC MDD dataset, as described below.

Association of the putative GLP-1R polymorphisms linked to response bias with depression diagnosis

We attempted to replicate the diagnostic analyses and test the association of significant SNPs linked to response bias, with MDD in a genome-wide meta-analysis of 75 607 cases and 231 747 controls assembled from 7 different cohorts as part of the PGC (Wray *et al.*, 2018). The design and quality control performed as part of the PGC have been extensively described elsewhere (Wray *et al.*, 2018). Briefly, individual genotype data for each of the participating cohorts were processed using the PGC ricopili pipeline to ensure standardised quality control, phasing and imputation protocols across all datasets. Initially, SNPs were excluded for excessive missingness (>0.05), differential missingness between cases and controls, deviations from expected autosomal heterozygosity and violations of Hardy Weinberg equilibrium ($p < 10^{-6}$ in controls and $p < 10^{-10}$ in cases). Samples with excessive missingness (>0.02) and outliers in ancestry were excluded. Pre-phasing and genotype imputation were performed using SHAPEIT/IMPUTE2 with a chunk size of 3 Mb and default parameters with the 1000 genomes phase 3 release as reference haplotypes. Post-impute quality control included selecting SNPs with high INFO (>0.8) scores and low missingness ($<1\%$). This yielded a sample size of 75 607 MDD cases and 231 747 controls and 9.6 million high-quality markers to be used for meta-analysis.

The diagnostic criteria used in each of the individual cohorts were carefully analysed by the PGC, and phenotype compatibility between cohorts was ensured by computing genetic correlations using common variants between each pair of individual cohorts and genetic risk prediction analyses.

Results

Association of GLP-1 polymorphisms with reward learning and anhedonia

The A allele in rs10305492 was significantly associated with decreased response bias in the PRT, and the C allele in rs1042044 was significantly associated with increased response

bias in a dominant model. Other SNPs in GLP-1R were not associated with response bias or SHAPS scores ($p > 0.05$) (Table 1).

C dominant model (CC and AC genotypes) in rs1042044 showed significantly lower anhedonia phenotype, compared to AA genotype ($\chi^2 = 5.2$, $p = 0.02$), based on the SHAPS scores. AG genotype in rs10305492 was not significantly different in the distribution of anhedonia phenotype, when compared to GG genotype in rs10305492 ($\chi^2 = 0.69$, $p = 0.4$).

GLP-1R polymorphisms and moderator variables of response bias

A multivariate linear regression was carried out to investigate whether age, gender, case-control status, discriminability, having A allele in rs10305492 and C allele in rs1042044 significantly predicted response bias. The results of the regression indicated that the model explained 7.8% of the variance and that the model was a significant predictor of response bias scores [($F(6,233)=3.28$, $p = 0.004$]. While A allele in rs10305492 ($B = -0.1$, $p = 0.004$) and C allele in rs1042044 significantly predicted response bias scores ($B = 0.47$, $p = 0.018$), age, sex, discriminability in PRT and case-control status did not (Table 2). In a second model where we added clinical variables, such as GDA, AA subscale of MASQ, YMRS, PANSS total and MADRS scores as covariates, instead of the case-control status, the results of the regression indicated that the model explained 9.4% of the variance and was a significant predictor of response bias [($F(10,222) = 2.3$, $p = 0.014$]. While discriminability ($B = -0.1$, $p = 0.04$), A allele in rs10305492 ($B = -0.15$, $p = 0.007$) and C allele in rs1042044 ($B = 0.044$, $p = 0.03$) significantly predicted response bias scores, none of the clinical scales, age and sex were a significant predictor of response bias (Table 3). When only A allele in rs10305492 and C allele in rs1042044, defined as dominant alleles, were included in the model to predict response bias, the model explained 5.2% of the variance [($F(2,258) = 7.04$, $p = 0.001$].

Association of the putative GLP-1R polymorphisms linked to response bias with depression diagnosis

The analysis of PGC MDD data as described in Sect. 2.2 showed no statistical association between the loci rs1042044 or rs10305492 and depressive disorder. The effect sizes and *p*-values from the association tests are shown in Table 4.

Discussion

To our knowledge, this study is the first study to assess the impact of GLP-1R polymorphisms on response bias in a reward learning task, anhedonia and depression phenotypes in humans.

The A allele in rs10305492 was significantly associated with decreased response bias in a dominant model (Table 1). However, as observed in many populations, A allele has a lower frequency (around 1–2%) compared to G allele [database of SNPs (dbSNPs). Bethesda (MD): National Center for Biotechnology Information, National Library of Medicine. Available from: http://www.ncbi.nlm.nih.gov/SNP/]. Here, we did not exclude this SNP in our analyses because it has been identified to be significantly associated with fasting glucose in several large-scale genetic studies (Wessel *et al.*, 2015) and is implicated to play an important role in modulating glucose levels, diabetes and cardiovascular risk (Scott *et al.*, 2016). The neurobiology of diabetes might be related to certain psychiatric disorders, and GLP-1R polymorphisms might also affect insulin physiology both in the brain and in the

Table 1. Mean response bias in PRT and SHAPS scores for each GLP-1R SNP's genotype

SNP	Genotype	Response bias			SHAPS		
		n	Mean response bias score	SD	*n*	Mean SHAPS score	SD
rs1030542	CC	12	0.137	0.128	12	0.750	1.765
	CT	63	0.103	0.166	62	1.113	1.775
	TT	76	0.099	0.179	75	1.347	2.496
p1 (T dominant)				0.536			0.249
p2 (C dominant)				0.731			0.653
rs10305421	CC	99	0.103	0.185	98	1.204	2.168
	CT	116	0.106	0.190	115	1.244	2.199
	TT	37	0.101	0.168	37	1.270	2.169
p1 (T dominant)				0.877			0.591
p2 (C dominant)				0.895			0.851
rs10305492	AG	3	-0.177	0.169	3	2.000	3.464
	GG	258	0.107	0.180	256	1.242	2.156
p1 (G dominant)							
p2 (A dominant)				**0.014**			0.979
rs1042044	AA	25	0.020	0.211	25	1.800	2.415
	AC	122	0.118	0.170	121	1.240	2.401
	CC	117	0.107	0.183	116	1.172	1.880
p1 (A dominant)				0.897			0.978
p2 (C dominant)				**0.033**			0.197
rs6923761	AA	50	0.118	0.188	49	1.245	1.843
	AC	137	0.116	0.165	137	1.153	2.169
	CC	77	0.074	0.202	76	1.474	2.419
p1 (C dominant)				0.487			0.487
p2 (A dominant)				0.128			0.327
rs5875654	AG	4	0.085	0.144	4	0.750	0.957
	GG	257	0.106	0.181	255	1.286	2.208
p1 (G dominant)							
p2 (A dominant)				0.852			1.000
rs761386	CC	244	0.107	0.175	242	1.310	2.257
	TC	19	0.071	0.255	19	0.737	0.806
p1 (T dominant)				0.258			0.913
p2 (C dominant)							

The boldface are significance at $p < 0.05$.

periphery. Therefore, rs10305492 could be one of the major shared pathways between peripheric and central effects of GLP-1. However, in our sample, only three individuals carried the A allele, consistent with the expected frequency. As such, it is possible for our results about rs10305492 to be false positive and the association of rs10305492 with reward learning needs to be validated in larger populations. Accordingly, this finding will not be further discussed or interpreted.

Our findings suggest that among GLP-1R SNPs, rs1042044 showed an association with reward learning and anhedonia in a cross-diagnostic sample of individuals with SZ and mood disorders (mainly, bipolar spectrum disorders), after controlling for possible

confounding effects (Tables 1, 2 and 3). However, this effect was small and it was not associated with depression diagnosis in the PGC sample. Also, our analysis for the first step (Table 1) was not corrected for multiple comparisons, but the association was still significant in the regression models.

GLP-1-related SNPs were not reported among the SNPs that reached a genome-wide significance for the association with anhedonia, but significant SNPs on different locations of chromosome 6 were identified in previous published GWASs for anhedonia (Ren *et al.*, 2018; Ward *et al.*, 2019). Different measurement methods for anhedonia and clinical features of the cohorts may account for the negative findings. The measure of anhedonia employed in Ward

Table 2. Association of A allele in rs10305492 or C allele in rs1042044 with response bias in PRT when controlling for case-control status, discriminability in PRT, age and sex

Variables	Coefficient (B)	SE	95% CI	*p*
Constant	0.195	0.098	0.002, 0.388	0.048
Case-control status	−0.021	0.027	−0.073, 0.032	0.437
Discriminability score in PRT	−0.089	0.047	−0.181, 0.003	0.057
A allele in rs10305492	−0.154	0.053	−0.25, −0.049	**0.004**
C allele in rs1042044	0.047	0.020	0.008, 0.086	**0.018**
Age	0.001	0.001	−0.001, 0.003	0.402
Sex	−0.015	0.024	−0.062, 0.033	0.543

The boldface are significance at $p < 0.05$.

Table 3. Association of A allele in rs10305492 and C allele in rs1042044 with response bias in PRT when controlling for discriminability in PRT, GDA subscale of MASQ, AA subscale of MASQ, YMRS, MADRS and PANSS total scores, age and sex

Variables	Coefficient (B)	SE	95% CI	*p*
Constant	0.252	0.107	0.042, 0.462	0.02
Discriminability score in PRT	−0.100	0.048	−0.194, 0.005	**0.04**
A allele in rs10305492	−0.149	0.055	−0.257, 0.042	**0.007**
C allele in rs1042044	0.044	0.020	0.004, 0.083	**0.03**
PANSS total score	−0.001	0.001	−0.002, 0.001	0.36
MADRS score	0.003	0.002	−0.001, 0.006	0.15
GDA subscore of MASQ	−0.001	0.003	−0.007, 0.005	0.73
AA subscore of MASQ	−0.001	0.002	−0.005, 0.003	0.60
YMRS score	−0.002	0.002	−0.005, 0.002	0.37
Age	0.001	0.001	−0.001, 0.003	0.43
Sex	−0.018	0.025	−0.068, 0.031	0.46

The boldface are significance at $p < 0.05$.

Table 4. Association of GLP-1R polymorphisms linked to response bias with depression in PGC depression GWAS, 2018 excluding 23andMe

SNP	A1	A2	OR	SE	*p*
rs1042044	A	C	0.99	0.0079	0.3
rs10305492	A	G	0.99	0.0349	0.8

et al. was based on a single question from a depression screening instrument within the preceding 2 weeks. The measure of anhedonia employed in Ren *et al.* was based on a composite 'baseline interest-activity' score, derived from anhedonia-related items in the Montgomery-Asberg Depression Scale, Hamilton Depression Scale and Beck Depression Inventory. Moreover, our study cohort included patients with psychotic disorders whereas the study cohort in Ward *et al.* was drawn from healthy individuals with high-socioeconomic status and education level and the study cohort in Ren *et al.* was drawn from individuals with unipolar depression diagnosis. Independent replication of association between anhedonia and reward-based phenotypes is warranted in future studies to validate our results.

A allele in rs1042044 has been previously related to altered anti-psychotic responses (Ramsey & Brennan, 2014) and homozygous C allele was related to higher morning cortisol levels (Sheikh *et al.*, 2010), which highlights a possible modulatory role of GLP-1 on HPA axis regulation and dopaminergic pathways. We hypothesise that C allele in rs1042044 might be modulating GLP-1R expression, function or distribution in the brain. While this genotype might modulate neurobiological responses to rewards and stress, it did not appear to increase vulnerability for depression per se.

Notably, activation of GLP-1R in human brain changes glucose utilisation in food-related reward areas, including the insula, striatum, orbitofrontal cortex, amygdala (Daniele *et al.*, 2015) and globus pallidus (Suchankova *et al.*, 2015), and this expression was related to altered responses to food or monetary rewards. However, comparisons with prior studies are limited, since they mainly focused on food reward, instead of anhedonia. GLP-1R might modulate hypothalamic responses related to satiety and food intake (Schlogl *et al.*, 2013). It may affect substance use development (Erreger *et al.*, 2012) without altering mood, as evidenced by a study linking GLP-1R 168Ser allele in s6923761 with higher alcohol consumption in humans (Suchankova *et al.*, 2015).

Growing evidence indicates that depression is a heterogenous diagnosis with multifactorial aetiology. Multiple independent genetic variants take part in its development (Mistry *et al.*, 2018; Wray *et al.*, 2018; Howard *et al.*, 2019), in addition to multiple environmental factors, affecting various regions in the brain (Howard *et al.*, 2019) and multiple cellular and molecular pathways (Pitsillou *et al.*, 2019). It is possible that rs1042044 is linked to reward processing phenotype specifically, consistent with pre-clinical findings about GLP-1 on reward circuitry. This effect in turn may modulate the propensity of development of anhedonia (described below). In rodents, GLP-1Rs are expressed in the mesolimbic reward pathway (Skibicka, 2013) and evidence from pre-clinical studies shows that activation of GLP-1 may decrease despair-like behaviour in the long term (Anderberg *et al.*, 2016). However, most of the studies on animals focused on addictive behaviours and found that administration of GLP-1 agonists decreases cocaine and amphetamine seeking behaviour, consumption doses and substance-induced behaviours (Graham *et al.*, 2013; Tuesta *et al.*, 2017). The pathways that GLP-1 uses in nucleus accumbens and ventral tegmental area could be mainly linked with food, substance and monetary-related reward, instead of other vegetative and mood-related symptoms of depression.

This study has several limitations, including relative small sample size, uncorrected *p* values for the first step of statistical analysis and limited statistical power for the reward learning analysis. Diagnoses assessed are both multifactorial and polygenic, and we probed putative relationship of a group of SNPs at GLP-1R without controlling for the polygenic risk score for other genes. Still, a reliable effect of GLP-1R polymorphisms on reward learning and anhedonia emerged.

In conclusion, our findings suggest a possible association of rs1042044 with reward learning and anhedonia. However, we could not find an association with depression diagnosis. Further studies with larger sample size are needed to replicate our findings and to evaluate the role of GLP-1R polymorphisms in the course and severity of reward-related disorders.

missing genetic data by CYC. Statistical analysis for McLean data has been conducted by HYE, and statistical analysis of PGC-MDD data has been conducted by VA. HYE wrote the draft and all authors contributed substantially to drafting the article or revising it critically for important intellectual content, and all authors approved the final version to be published.

Conflict of interest. Over the past 3 years, DAP has received consulting fees from BlackThorn Therapeutics, Boehringer Ingelheim, Compass, Takeda and an honorarium from Alkermes for activities unrelated to the current research. Dr. Pizzagalli has a financial interest in BlackThorn Therapeutics, which has licensed the copyright to the PRT through Harvard University. Dr. Pizzagalli's interests were reviewed and are managed by McLean Hospital and Partners HealthCare in accordance with their conflict of interest policies. DO served on a scientific advisory board for Neurocrine Inc on 12/2016.

Ethical standards. This study was approved by McLean Hospital Institutional Review Board. All subjects provided a written informed consent and procedures were in accordance with the Declaration of Helsinki.

The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008.

References

Allen JG (1998) User's guide, administration booklet, and scoresheet for the Structured Clinical Interview for DSM-IV Axis I Disorders, clinician version. *Bulletin of the Menninger Clinic* **62**, 126–126.

Auton A, Abecasis GR, Altshuler DM, Durbin RM, Bentley DR, Chakravarti A, Clark AG, Donnelly P, Eichler EE and Flicek P (2015) A global reference for human genetic variation. *Nature* **526**, 68–74.

Anderberg RH, Richard JE, Hansson C, Nissbrandt H, Bergquist F and Skibicka KP (2016) GLP-1 is both anxiogenic and antidepressant; divergent effects of acute and chronic GLP-1 on emotionality. *Psychoneuroendocrinology* **65**, 54–66.

Aroda VR (2018) A review of GLP-1 receptor agonists: evolution and advancement, through the lens of randomised controlled trials. *Diabetes, Obesity and Metabolism* **20** Suppl. 1, 22–33.

Brunetti L, Orlando G, Recinella L, Leone S, Ferrante C, Chiavaroli A, Lazzarin F and Vacca M (2008) Glucagon-like peptide 1 (7-36) amide (GLP-1) and exendin-4 stimulate serotonin release in rat hypothalamus. *Peptides* **29**, 1377–1381.

Chowen JA, de Fonseca FR, Alvarez E, Navarro M, Garcia-Segura LM and Blazquez E (1999) Increased glucagon-like peptide-1 receptor expression in glia after mechanical lesion of the rat brain. *Neuropeptides* **33**, 212–215.

Clark-Elford R, Nathan PJ, Auyeung B, Voon V, Sule A, Müller U, Dudas R, Sahakian BJ, Phan KL and Baron-Cohen S (2014) The effects of oxytocin on social reward learning in humans. *International Journal of Neuropsychopharmacology* **17**, 199–209.

Daniele G, Iozzo P, Molina-Carrion M, Lancaster J, Ciociaro D, Cersosimo E, Tripathy D, Triplitt C, Fox P, Musi N and DeFronzo R (2015) Exenatide regulates cerebral glucose metabolism in brain areas associated with glucose homeostasis and reward system. *Diabetes* **64**, 3406–3412.

Delgado MR, Miller MM, Inati S and Phelps EA (2005) An fMRI study of reward-related probability learning. *Neuroimage* **24**, 862–873.

de Luis DA, Aller R, Izaola O and Bachiller R (2015) Role of rs6923761 gene variant in glucagon-like peptide 1 receptor in basal GLP-1 levels,

cardiovascular risk factor and serum adipokine levels in naive type 2 diabetic patients. *Journal of Endocrinological Investigation* **38**, 143–147.

de Luis DA, Pacheco D, Aller R and Izaola O (2014a) Role of the rs6923761 gene variant in glucagon-like peptide 1 receptor gene on cardiovascular risk factors and weight loss after biliopancreatic diversion surgery. *Annals of Nutrition and Metabolism* **65**, 259–263.

de Luis DA, Pacheco D, Aller R, Izaola O and Bachiller R (2014b) Roles of rs 6923761 gene variant in glucagon-like peptide 1 receptor on weight, cardiovascular risk factor and serum adipokine levels in morbid obese patients. *Nutricion Hospitalaria* **29**, 889–893.

Detka J, Ślusarczyk J, Kurek A, Kucharczyk M, Adamus T, Konieczny P, Kubera M, Basta-Kaim A, Lasoń W and Budziszewska B (2019) Hypothalamic insulin and glucagon-like peptide-1 levels in an animal model of depression and their effect on corticotropin-releasing hormone promoter gene activity in a hypothalamic cell line. *Pharmacological Reports* **71**, 338–346.

Dichter GS, Damiano CA and Allen JA (2012) Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings. *Journal of Neurodevelopmental Disorders* **4**, 19.

Drucker DJ (2006) The biology of incretin hormones. *Cell Metabolism* **3**, 153–165.

Duman RS and Aghajanian GK (2012) Synaptic dysfunction in depression: potential therapeutic targets. *Science* **338**, 68–72.

Erbil D, Eren CY, Demirel C, Kucuker MU, Solaroglu I and Eser HY (2019) GLP-1's role in neuroprotection: a systematic review. *Brain Injury* 1–85.

Erreger K, Davis AR, Poe AM, Greig NH, Stanwood GD and Galli A (2012) Exendin-4 decreases amphetamine-induced locomotor activity. *Physiology & Behavior* **106**, 574–578.

Farr OM, Sofopoulos M, Tsoukas MA, Dincer F, Thakkar B, Sahin-Efe A, Filippaios A, Bowers J, Srnka A, Gavrieli A and Ko BJ (2016) GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial. *Diabetologia* **59**, 954–965.

Franken IHA, Rassin E and Muris, P (2007) The assessment of anhedonia in clinical and non-clinical populations: further validation of the Snaith-Hamilton Pleasure Scale (SHAPS). *Journal of Affective Disorders* **99**, 83–89.

Gold MS, Blum K, Febo M, Baron D, Modestino EJ, Elman I and Badgaiyan RD (2018) Molecular role of dopamine in anhedonia linked to reward deficiency syndrome (RDS) and anti- reward systems. *Front Biosci (Schol Ed)* **10**, 309–325.

Graham DL, Erreger K, Galli A and Stanwood GD (2013) GLP-1 analog attenuates cocaine reward. *Molecular Psychiatry* **18**, 961–962.

Hall MH, Chen CY, Cohen BM, Spencer KM, Levy DL, Öngür D and Smoller JW (2015) Genomewide association analyses of electrophysiological endophenotypes for schizophrenia and psychotic bipolar disorders: a preliminary report. *American Journal of Medical Genetics Part B-Neuropsychiatric Genetics* **168**, 151–161.

Heppner KM, Kirigiti M, Secher A, Paulsen SJ, Buckingham R, Pyke C, Knudsen LB, Vrang N and Grove KL (2015) Expression and distribution of glucagon-like peptide-1 receptor mRNA, protein and binding in the male nonhuman primate (Macaca mulatta) brain. *Endocrinology* **156**, 255–267.

Hernandez NS, O'Donovan B, Ortinski PI and Schmidt HD (2019) Activation of glucagon-like peptide-1 receptors in the nucleus accumbens attenuates cocaine seeking in rats. *Addiction Biology* **24**, 170–181.

Howard DM, Adams MJ, Clarke TK, Hafferty JD, Gibson J, Shirali M, Coleman JR, Hagenaars SP, Ward J, Wigmore EM and Alloza C (2019) Genome-wide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions. *Nature Neuroscience* **22**, 343–352.

Howie B, Marchini J and Stephens M (2011) Genotype imputation with thousands of genomes. *G3-Genes Genomes Genetics* **1**, 457–469.

Kappe C, Tracy LM, Patrone C, Iverfeldt K and Sjoholm A (2012) GLP-1 secretion by microglial cells and decreased CNS expression in obesity. *Journal of Neuroinflammation* **9**, 276.

Koshal P, Jamwal S and Kumar P (2018) Glucagon-like Peptide-1 (GLP-1) and neurotransmitters signaling in epilepsy: an insight review. *Neuropharmacology* **136**, 271–279.

Krass M, Rünkorg K, Vasar E and Volke V. (2012) Acute administration of GLP-1 receptor agonists induces hypolocomotion but not anxiety in mice. *Acta Neuropsychiatrica* **24**(5), 296–300.

Krass M, Volke A, Rünkorg K, Wegener G, Lund S, Abildgaard A, Vasar E and Volke V (2015) GLP-1 receptor agonists have a sustained stimulatory effect on corticosterone release after chronic treatment. *Acta Neuropsychiatrica* **27**(1), 25–32.

Lewandowski KE, Whitton AE, Pizzagalli DA, Norris LA, Ongur D and Hall MH (2016) Reward learning, neurocognition, social cognition, and symptomatology in psychosis. *Frontiers in Psychiatry* **7**.

Luijten M, Schellekens AF, Kuhn S, Machielse MW and Sescousse G (2017) Disruption of Reward processing in addiction: an image-based meta-analysis of functional magnetic resonance imaging studies. *JAMA Psychiatry* **74**, 387–398.

Malendowicz LK, Nussdorfer GG, Nowak KW, Ziolkowska A, Tortorella C and Trejter M. (2003). Exendin-4, a GLP-1 receptor agonist, stimulates pituitary-adrenocortical axis in the rat: investigations into the mechanism (s) underlying Ex4 effect. *International Journal of Molecular Medicine* **12**(2), 237–241.

Mansur RB, Fries GR, Trevizol AP, Subramaniapillai M, Lovshin J, Lin K, Vinberg M, Ho RC, Brietzke E and McIntyre RS (2019) The effect of body mass index on glucagon-like peptide receptor gene expression in the post mortem brain from individuals with mood and psychotic disorders. *European Neuropsychopharmacology* **29**, 137–146.

Mistry S, Harrison JR, Smith DJ, Escott-Price V and Zammit S (2018) The use of polygenic risk scores to identify phenotypes associated with genetic risk of bipolar disorder and depression: A systematic review. *Journal of Affective Disorders* **234**, 148–155.

Nusslock, R and Alloy, LB (2017) Reward processing and mood-related symptoms: an RDoC and translational neuroscience perspective. *Journal of Affective Disorders* **216**, 3–16.

O'Connell J, Sharp K, Shrine N, Wain L, Hall I, Tobin M, Zagury JF, Delaneau O and Marchini J (2016) Haplotype estimation for biobank-scale data sets. *Nature Genetics* **48**, 817–820.

Peterson DA, Lotz DT, Halgren E, Sejnowski TJ and Poizner H (2011) Choice modulates the neural dynamics of prediction error processing during rewarded learning. *Neuroimage* **54**, 1385–1394.

Pitsillou E, Bresnehan SM, Kagarakis EA, Wijoyo SJ, Liang J, Hung A and Karagiannis TC (2019) The cellular and molecular basis of major depressive disorder: towards a unified model for understanding clinical depression. *Molecular Biology Reports* **47**(1), 753–770.

Pizzagalli DA, Iosifescu D, Hallett LA, Ratner KG and Fava M (2008) Reduced hedonic capacity in major depressive disorder: evidence from a probabilistic reward task. *Journal of Psychiatric Research* **43**, 76–87.

Pizzagalli DA, Jahn AL and O'Shea JP (2005) Toward an objective characterization of an anhedonic phenotype: a signal-detection approach. *Biological Psychiatry* **57**(4), 319–327.

Ramsey TL and Brennan MD (2014) Glucagon-like peptide 1 receptor (GLP1R) haplotypes correlate with altered response to multiple antipsychotics in the CATIE trial. *Schizophrenia Research* **160**, 73–79.

Ren H, Fabbri A, Uher R, Rietschel M, Mors O, Henigsberg N, Hauser J, Zobel A, Maier W, Dernovsek MZ and Souery D (2018) Genes associated with anhedonia: a new analysis in a large clinical trial (GENDEP). *Translational Psychiatry* **8**(1), 1–11.

Rinaman L and Rothe EE (2002) GLP-1 receptor signaling contributes to anorexigenic effect of centrally administered oxytocin in rats. *American Journal of Physiology-Regulatory, Integrative and Comparative Physiology* **283**, R99–R106.

Rizvi SJ, Pizzagalli DA, Sproule BA and Kennedy SH (2016) Assessing anhedonia in depression: potentials and pitfalls. *Neuroscience and Biobehavioral Reviews* **65**, 21–35.

Sarkar S, Fekete C, Legradi G and Lechan RM (2003) Glucagon like peptide-1 (7-36) amide (GLP-1) nerve terminals densely innervate corticotropin-releasing hormone neurons in the hypothalamic paraventricular nucleus. *Brain Research* **985**, 163–168.

Sathananthan A, Dalla Man CD, Micheletto F, Zinsmeister AR, Camilleri M, Giesler PD, Laugen JM, Toffolo G, Rizza RA, Cobelli C and Vella A (2010) Common genetic variation in GLP1R and insulin secretion in response to exogenous GLP-1 in nondiabetic subjects: a pilot study. *Diabetes Care* **33**, 2074–2076.

Schlögl H, Kabisch S, Horstmann A, Lohmann G, Müller K, Lepsien J, Busse-Voigt F, Kratzsch J, Pleger B, Villringer A and Stumvoll M (2013) Exenatide-induced reduction in energy intake is associated with increase in hypothalamic connectivity. *Diabetes Care* **36**, 1933–1940.

Scott RA, Freitag DF, Li L, Chu AY, Surendran P, Young R, Grarup N, Stancáková A, Chen Y, Varga TV and Yaghootkar H (2016) A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease. *Science Translational Medicine* **8**, 341ra76.

Sharma AN, Ligade SS, Sharma JN, Shukla P, Elased KM and Lucot JB (2015) GLP-1 receptor agonist liraglutide reverses long-term atypical antipsychotic treatment associated behavioral depression and metabolic abnormalities in rats. *Metabolic Brain Disease* **30**, 519–527.

Sheikh HI, Dougherty LR, Hayden EP, Klein DN and Singh SM (2010) Glucagon-like peptide-1 receptor gene polymorphism (Leu260Phe) is associated with morning cortisol in preschoolers. *Progress in Neuro-Psychopharmacology and Biological Psychiatry* **34**, 980–983.

Skibicka KP (2013) The central GLP-1: implications for food and drug reward. *Frontiers Neuroscience* **7**, 181.

Snaith RP, Hamilton M, Morley S, Humayan A, Hargreaves D and Trigwell P (1995) A scale for the assessment of Hedonic tone – the Snaith-Hamilton pleasure scale. *British Journal of Psychiatry* **167**, 99–103.

Suchankova P, Yan J, Schwandt ML, Stangl BL, Caparelli EC, Momenan R, Jerlhag E, Engel JA, Hodgkinson CA, Egli M and Lopez MF (2015) The glucagon-like peptide-1 receptor as a potential treatment target in alcohol use disorder: evidence from human genetic association studies and a mouse model of alcohol dependence. *Translational Psychiatry* **5**.

Tuesta LM, Chen Z, Duncan A, Fowler CD, Ishikawa M, Lee BR, Liu XA, Lu Q, Cameron M, Hayes MR and Kamenecka TM (2017) GLP-1 acts on habenular avoidance circuits to control nicotine intake. *Nature Neuroscience* **20**, 708–716.

Vrieze E, Pizzagalli DA, Demyttenaere K, Hompes T, Sienaert P, de Boer P, Schmidt M and Claes S (2013) Reduced reward learning predicts outcome in major depressive disorder. *Biological Psychiatry* **73**, 639–645.

Ward J, Lyall LM, Bethlehem RA, Ferguson A, Strawbridge RJ, Lyall DM, Cullen B, Graham N, Johnston KJ, Bailey ME and Murray GK (2019). Novel genome-wide associations for anhedonia, genetic correlation with psychiatric disorders, and polygenic association with brain structure. *Translational Psychiatry* **9**(1), 1–9.

Wessel J, Chu AY, Willems SM, Wang S, Yaghootkar H, Brody JA, Dauriz M, Hivert MF, Raghavan S, Lipovich L and Hidalgo B (2015) Low-frequency and rare exome chip variants associate with fasting glucose and type 2 diabetes susceptibility. *Nature Communications* **6**, 5897.

Whitton AE, Treadway MT and Pizzagalli DA (2015) Reward processing dysfunction in major depression, bipolar disorder and schizophrenia. *Current Opinion in Psychiatry* **28**, 7–12.

Williams DL, Lilly NA, Edwards IJ, Yao P, Richards JE and Trapp S (2018) GLP-1 action in the mouse bed nucleus of the stria terminalis. *Neuropharmacology* **131**, 83–95.

Wimmer GE, Braun EK, Daw ND and Shohamy D (2014) Episodic memory encoding interferes with reward learning and decreases striatal prediction errors. *Journal of Neuroscience* **34**, 14901–14912.

Wray NR, Ripke S, Mattheisen M, Trzaskowski M, Byrne EM, Abdellaoui A, Adams MJ, Agerbo E, Air TM, Andlauer TM and Bacanu SA (2018) Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. *Nature Genetics* **50**, 668–681.

Zheng HY, Reiner DJ, Hayes MR and Rinaman L (2019) Chronic suppression of glucagon-like peptide-1 receptor (GLP1R) mRNA translation in the rat bed nucleus of the stria terminalis reduces anxiety-like behavior and stress-induced hypophagia, but prolongs stress-induced elevation of plasma corticosterone. *Journal of Neuroscience* **39**, 2649–2663.